Table 4.

Peptidomimetic and small molecular covalent SARS-CoV Mpro inhibitors.

Entry	Comp	PDB	Activity against Mpro	Year	Reference
1	A021	--	IC50 = 50 nM	2004	[27]
2	A022	2A5K	kinact/Ki = 1900 (±400) M−1s−1	2005	[44]
3	A023	2GX4	Ki = 53 nM	2006	[45]
4	A024	2QIQ	IC50 = 80 μM	2007	[46]
5	A025	--	IC50 = 50 nM; antiviral activity EC50 = 6.9 μM	2008	[47]
6	A026	--	IC50 = 2.20 μM	2009	[48]
7	A027	--	Ki = 0.003 μM	2013	[49]
8	A028	--	Ki = 0.33 μM	2013	[50]
9	A029	--	Ki = 0.065 μM	2013	[51]
10	A030	5N19	IC50 = 1.95 μM	2020	[3]
11	A031	--	IC50 = 0.71 μM	2020	[3]